Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pleckstrin homology domain-containing family A member 4 (PLEKHA4) is a plasma membrane-associated adaptor protein characterized by an N-terminal pleckstrin homology (PH) domain, which mediates specific binding to phosphoinositides such as PI(4,5)P2 and/or PtdIns3P[1][3]. PLEKHA4 assembles into higher-order structures at PI(4,5)P2-enriched regions of the plasma membrane and recruits the E3 ubiquitin ligase adaptor KLHL12, attenuating CUL3-KLHL12-mediated polyubiquitination of Dishevelled (DVL)[1]. This regulation modulates both canonical (β-catenin dependent) and non-canonical (planar cell polarity) Wnt signaling by setting DVL protein levels and membrane localization[1]. Elevated PLEKHA4 expression is observed in some melanomas[2][3], implicating potential roles in oncogenic signaling, though it is not a validated therapeutic target, nor are there known direct drug interactions. It has no known role as a classical receptor, enzyme, or transporter, but functions as a phosphoinositide-binding adaptor protein involved in membrane signaling organization and the spatial regulation of ubiquitination machinery[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pleckstrin homology domain-containing family A member 4 (PLEKHA4).